Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 6/2018

Open Access 01-12-2018 | Original article

Biocompatibility of a new PD solution for Japan, Reguneal™, measured as in vitro proliferation of fibroblasts

Authors: Bart Dioos, Goedele Paternot, Rose-Marie Jenvert, Annick Duponchelle, Mark R. Marshall, Migaku Nakajima, Edward Ramirez Ganoza, James A. Sloand, Anders P. Wieslander

Published in: Clinical and Experimental Nephrology | Issue 6/2018

Login to get access

Abstract

Background

The aim of this study was to investigate in vitro biocompatibility of Reguneal™, a new bicarbonate containing peritoneal dialysis fluid (PDF) for Japan, and compare it with other PDFs available in that country.

Methods

We assessed basal cytotoxicity using in vitro proliferation of cultured fibroblasts, L-929, determining the quantity of living cells by the uptake of Neutral Red. Levels of ten glucose degradation products (GDPs) were measured by a validated ultrahigh-performance liquid chromatography method in combination with an ultraviolet detector. We compared inhibition of fibroblast cell growth between brands of PDF, adjusting for dextrose and GDP concentrations using random-effects mixed models.

Results

The results demonstrate that cytotoxicity of Reguneal™ is comparable to a sterile-filtered control and is less cytotoxic than most of the other PDFs, most of which significantly inhibited cell growth. As a “class effect”, increasing dextrose and GDP concentrations were non-significantly but positively associated with cytotoxicity. As a “brand effect”, these relationships varied widely between brands, and some PDFs had significant residual effects on basal cytotoxicity through mechanisms that were unassociated with either dextrose or GDP concentration.

Conclusion

Our study suggests that Reguneal™ is a biocompatible PDF. The results of our study also highlight that dextrose and GDPs are important for biocompatibility, but alone are not a complete surrogate. The results of our study need to be confirmed in other tissue culture models, and should lead to further research on determinants of biocompatibility and the effect of such PDFs on clinical outcomes.
Appendix
Available only for authorised users
Literature
1.
Nakayama M, Ishida M, Ogihara M, Hanaoka K, Tamura M, Kanai H, et al. Social functioning and socioeconomic changes after introduction of regular dialysis treatment and impact of dialysis modality: a multi-centre survey of Japanese patients. Nephrology (Carlton). 2015;20(8):523–30. https://​doi.​org/​10.​1111/​nep.​12482.CrossRef
2.
3.
Nakamoto H, Kawaguchi Y, Suzuki H. Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. Adv Perit Dial. 2002;18:119–23.PubMed
4.
Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004;44(4):729–37.CrossRef
5.
6.
Kawanishi H, Nakayama M, Miyazaki M, Honda K, Tomo T, Kasai K, et al. Prospective multicenter observational study of encapsulating peritoneal sclerosis with neutral dialysis solution–the NEXT-PD study. Adv Perit Dial. 2010;26:71–4.PubMed
7.
8.
9.
Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H, et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int. 2005;25(Suppl 4):S83-95.PubMed
10.
Nakamoto H. Encapsulating peritoneal sclerosis–a clinician’s approach to diagnosis and medical treatment. Perit Dial Int. 2005;25(Suppl 4):S30-8.PubMed
11.
12.
Hoshino T, Ishii H, Kitano T, Shindo M, Miyazawa H, Yamada H, et al. Effects of a new bicarbonate/lactate-buffered neutral peritoneal dialysis fluid for peritoneal failure in patients undergoing peritoneal dialysis. Discov Med. 2016;21(114):81–8.PubMed
13.
Sturgeon RJ, Athanikar NK, Hartison HA, Henry RS, Jurgens RW Jr, Welco AD. Degradation of dextrose during heating under simulated sterilization. J Parent Drug Assoc. 1980;34(3):175–82.
14.
Kidney Disease: Improving Global Outcomes (KDIGO) Bone Metabolism and Disease in Chronic Kidney Disease Working Group (2017) KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention,and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 7(1):1–59. https://​doi.​org/​10.​1016/​j.​kisu.​2017.​04.​001.CrossRef
15.
Schroder CH. The choice of dialysis solutions in pediatric chronic peritoneal dialysis: guidelines by an ad hoc European committee. Perit Dial Int. 2001;21(6):568–74.PubMed
16.
Wang AYM, Brimble KS, Brunier G, Holt SG, Jha V, Johnson DW, et al. ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients part I—assessment and management of various cardiovascular risk factors. Perit Dial Int J Int Soc Perit Dial. 2015;35(4):379–87. https://​doi.​org/​10.​3747/​pdi.​2014.​00279.CrossRef
17.
18.
19.
Wieslander AP, Nordin MK, Kjellstrand PT, Boberg UC. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int. 1991;40(1):77–9.CrossRef
20.
21.
22.
23.
Coles GA. Biocompatibility and new fluids. Perit Dial Int. 1999;19(Suppl 2):S267–70.PubMed
24.
Witowski J, Bender TO, Wisniewska-Elnur J, Ksiazek K, Passlick-Deetjen J, Breborowicz A, et al. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int. 2003;23(4):381–90.PubMed
25.
Witowski J, Jorres A. Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. Perit Dial Int. 2005;25(Suppl 3):S31–4.PubMed
26.
Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jorres A, Lage C, et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transpl. 2004;19(4):917–24. https://​doi.​org/​10.​1093/​ndt/​gfh013.CrossRef
27.
Martinson E, Wieslander A, Kjellstrand P, Boberg U. Toxicity of heat sterilized peritoneal dialysis fluids is derived from degradation of glucose. Asaio J. 1992;38(3):M370–2.CrossRef
28.
Erixon M, Linden T, Kjellstrand P, Carlsson O, Ernebrant M, Forsback G, et al. PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization. Perit Dial Int. 2004;24(4):392–8.PubMed
29.
Kjellstrand P, Martinson E, Wieslander A, Kjellstrand K, Jeppsson E, Svensson E, et al. Degradation in peritoneal dialysis fluids may be avoided by using low pH and high glucose concentration. Perit Dial Int. 2001;21(4):338–44.PubMed
30.
31.
Wieslander A, Linden T, Kjellstrand P. Glucose degradation products in peritoneal dialysis fluids: how they can be avoided. Perit Dial Int. 2001;21(Suppl 3):S119–24.PubMed
32.
Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R, Rippe B. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int. 1995;15(2):158–64.PubMed
33.
Pedersen FB, Ryttov N, Deleuran P, Dragsholt C, Kildeberg P. Acetate versus lactate in peritoneal dialysis solutions. Nephron. 1985;39(1):55–8.CrossRef
34.
Liberek T, Topley N, Jorres A, Petersen MM, Coles GA, Gahl GM, et al. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron. 1993;65(2):260–5.CrossRef
35.
Schambye HT. Effect of different buffers on the biocompatibility of CAPD solutions. Perit Dial Int. 1996;16(Suppl 1):S130–6.PubMed
36.
37.
Schambye HT, Pedersen FB, Wang P. Bicarbonate is not the ultimate answer to the biocompatibility problems of CAPD solutions: a cytotoxicity test of CAPD solutions and effluents. Adv Perit Dial. 1992;8:42–6.PubMed
38.
Schambye HT, Flesner P, Pedersen RB, Hardt-Madsen M, Chemnitz J, Christensen HK, et al. Bicarbonate- versus lactate-based CAPD fluids: a biocompatibility study in rabbits. Perit Dial Int. 1992;12(3):281–6.PubMed
39.
Schambye HT, Pedersen FB, Christensen HK, Berthelsen H, Wang P. The cytotoxicity of continuous ambulatory peritoneal dialysis solutions with different bicarbonate/lactate ratios. Perit Dial Int. 1993;13(Suppl 2):S116–8.PubMed
40.
Topley N, Mackenzie R, Williams JD. Acute in vivo exposure bicarbonate/lactate (TBL) and bicarbonate (TB) buffered peritoneal dialysis fluids (PDF) improves LPS driven peritoneal macrophage TNF a secretion. Perit Dial Int. 1997;17(Suppl 1):S39.
41.
Topley N, Mackenzie R, Williams JD. Long-term in vivo exposure to bicarbonate-buffered PDF (TBL) improves ex vivo peritoneal macrophage function, comparison with bicarbonate (TB) or lactate buffered PDF (PD4). Perit Dial Int. 1997;17(Suppl 1):S39.
42.
43.
Brown EA, Van Biesen W, Finkelstein FO, Hurst H, Johnson DW, Kawanishi H, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int. 2009;29(6):595–600.PubMed
44.
45.
Nilsson-Thorell CB, Muscalu N, Andren AH, Kjellstrand PT, Wieslander AP. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int. 1993;13(3):208–13.PubMed
46.
Holmes CJ, Faict D. Peritoneal dialysis solution biocompatibility: definitions and evaluation strategies. Kidney Int Suppl. 2003; (88):S50–6.CrossRef
47.
Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol. 2000;11(4):729–39.PubMed
48.
Witowski J, Jorres A. Glucose degradation products: relationship with cell damage. Perit Dial Int. 2000;20(Suppl 2):S31–6.PubMed
49.
Jorres A, Witkowski JM, Korybalska K, Breborowicz A, Gahl GM, Frei U, et al. Toxicity of glucose degradation products towards human peritoneal mesothelial cell and L929 fibroblasts. Kidney Blood Press Res. 1998;21:200.
50.
Cooker LA, Luneburg P, Faict D, Choo C, Holmes CJ. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int. 1997;17(4):373–8.PubMed
51.
Wieslander AP, Andren AH, Nilsson-Thorell C, Muscalu N, Kjellstrand PT, Rippe B. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int. 1995;15(8):348–52.PubMed
52.
Wieslander A, Linden T. Glucose degradation and cytotoxicity in PD fluids. Perit Dial Int. 1996;16(Suppl 1):S114–8.PubMed
53.
Lee DH, Choi SY, Ryu HM, Kim CD, Park SH, Chung HY, et al. 3,4-dideoxyglucosone-3-ene induces apoptosis in human peritoneal mesothelial cells. Perit Dial Int. 2009;29(1):44–51.PubMed
54.
55.
Ponsoda X, Jover R, Nunez C, Royo M, Castell JV, Gomez-Lechon MJ. Evaluation of the cytotoxicity of 10 chemicals in human and rat hepatocytes and in cell lines: correlation between in vitro data and human lethal concentration. Toxicol In Vitro Int J Publ Assoc BIBRA. 1995;9(6):959–66.CrossRef
56.
Metadata
Title
Biocompatibility of a new PD solution for Japan, Reguneal™, measured as in vitro proliferation of fibroblasts
Authors
Bart Dioos
Goedele Paternot
Rose-Marie Jenvert
Annick Duponchelle
Mark R. Marshall
Migaku Nakajima
Edward Ramirez Ganoza
James A. Sloand
Anders P. Wieslander
Publication date
01-12-2018
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 6/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-018-1602-2

Other articles of this Issue 6/2018

Clinical and Experimental Nephrology 6/2018 Go to the issue

Guideline

Guidelines for clinical evaluation of chronic kidney disease

Original article

Decreased KLHL3 expression is involved in the pathogenesis of pseudohypoaldosteronism type II caused by cullin 3 mutation in vivo

Correction

Correction to: Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on dialysis

Original article

Dipstick proteinuria and all-cause mortality among the general population

Images in Nephrology

Imaging of bilateral Ask-Upmark kidney

Original article

Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits